← Back to Clinical Trials
Recruiting Phase 2 NCT07073287

NCT07073287 Efficacy of Cerebello-spinal Direct Current Stimulation (csDCS) on Functional Mobility in Chronic Stroke Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07073287
Status Recruiting
Phase Phase 2
Sponsor Universidade Federal de Pernambuco
Condition Stroke Rehabilitation
Study Type INTERVENTIONAL
Enrollment 30 participants
Start Date 2024-05-01
Primary Completion 2026-01-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 75 Years
Study Type INTERVENTIONAL
Interventions
Cerebello-spinal direct current stimulationSham Comparator

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.

This trial targets 30 participants in total. It began in 2024-05-01 with a primary completion date of 2026-01-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The aim of this clinical trial is to determine if cerebello-spinal direct current stimulation (csDCS) is effective in treating gait disorders in individuals with chronic stroke. Additionally, the trial seeks to evaluate the safety of this technique. The primary objectives include: Investigating whether cerebello-spinal direct current stimulation improves gait and functional mobility in participants with chronic stroke. Assessing any potential side effects associated with the method. Researchers will conduct a comparative analysis between cerebello-spinal direct current stimulation and a sham procedure (which mimics the stimulation without any actual effect) to assess its effectiveness in addressing gait disorders and enhancing mobility. Participants in the trial will: Undergo cerebello-spinal direct current stimulation combined with treadmill training or a sham procedure with treadmill training daily over a two-week period.

Eligibility Criteria

Inclusion Criteria: * Confirmation of Stroke by digital or physical imaging or medical report * Gait impairment * Stroke with at least 6 months after ictus Exclusion Criteria: * Metallic implants in spinal cord * Major orthopedic/rheumatological disorders * Inability of verbal or non-verbal communication

Contact & Investigator

Central Contact

DANIEL MELO, Bachelor in physical therapy

✉ gmelodaniel@gmail.com

📞 81995173332

Frequently Asked Questions

Who can join the NCT07073287 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Stroke Rehabilitation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT07073287 trial and what does that mean for participants?

Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.

Is NCT07073287 currently recruiting?

Yes, NCT07073287 is actively recruiting participants. Contact the research team at gmelodaniel@gmail.com for enrollment information.

Where is the NCT07073287 trial being conducted?

This trial is being conducted at João Pessoa, Brazil, Recife, Brazil, Rio de Janeiro, Brazil.

Who is sponsoring the NCT07073287 clinical trial?

NCT07073287 is sponsored by Universidade Federal de Pernambuco. The trial plans to enroll 30 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology